Healthcare is the most undervalued sector, with insider buying at a 20-year high: Lilly’s $4.5 million in internal purchases reflects a bottoming pattern, supported by GLP-1 demand projected to grow 40% YoY through 2030. The company’s 80% success rate in phase 3 trials and $10 billion R&D budget ensure long-term growth, making it a top pick for investors seeking exposure to transformative drugs.
Meta Reaffirms Content Leadership with Strong Ad Growth and Strategic Investments
The full POL migration enhances efficiency: transaction speeds increased 20% and costs dropped 50%, driving 30% TVL growth in 2023. With 5,000 active developers and $100 million in grants, Polygon’s DeFi and gaming ecosystem supports a 20-30% rally, making it a high-conviction buy for Layer 2 exposure.
Meta Reaffirms Content Leadership with Strong Ad Growth and Strategic Investments
The full POL migration enhances efficiency: transaction speeds increased 20% and costs dropped 50%, driving 30% TVL growth in 2023. With 5,000 active developers and $100 million in grants, Polygon’s DeFi and gaming ecosystem supports a 20-30% rally, making it a high-conviction buy for Layer 2 exposure.
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
testtest news
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Massive AI Expansion Across Creative Cloud Massive AI Expansion Across Creative Cloud
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Amazon is a top pick for a decade-long hold
